160 related articles for article (PubMed ID: 30094404)
1. Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease.
Margini C; Murgia G; Stirnimann G; De Gottardi A; Semmo N; Casu S; Bosch J; Dufour JF; Berzigotti A
Hepatol Commun; 2018 Aug; 2(8):929-940. PubMed ID: 30094404
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease.
Mendoza Y; Cocciolillo S; Murgia G; Chen T; Margini C; Sebastiani G; Berzigotti A
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3017-3025.e6. PubMed ID: 32289534
[TBL] [Abstract][Full Text] [Related]
3. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
[TBL] [Abstract][Full Text] [Related]
4. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.
Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Liver Int; 2019 Jan; 39(1):127-135. PubMed ID: 30107095
[TBL] [Abstract][Full Text] [Related]
5. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
Thorhauge KH; Semmler G; Johansen S; Lindvig KP; Kjærgaard M; Hansen JK; Torp N; Hansen CD; Andersen P; Hofer BS; Gu W; Israelsen M; Mandorfer M; Reiberger T; Trebicka J; Thiele M; Krag A;
J Hepatol; 2024 Jul; 81(1):23-32. PubMed ID: 38428644
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
8. Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements.
Barisic-Jaman M; Milosevic M; Skurla V; Dohoczky D; Stojic J; Dinjar Kujundzic P; Cigrovski Berkovic M; Majic-Tengg A; Matijaca A; Lucijanic T; Kardum-Pejic M; Pandzic Jaksic V; Marusic S; Grgurevic I
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397925
[TBL] [Abstract][Full Text] [Related]
9. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
11. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
Gawrieh S; Vilar-Gomez E; Wilson LA; Pike F; Kleiner DE; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Kowdley KV; Hameed B; Tonascia J; Loomba R; Sanyal AJ; Chalasani N;
J Hepatol; 2024 May; ():. PubMed ID: 38762169
[TBL] [Abstract][Full Text] [Related]
12. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
Semmler G; Yang Z; Fritz L; Köck F; Hofer BS; Balcar L; Hartl L; Jachs M; Stopfer K; Schedlbauer A; Neumayer D; Maurer J; Müllner-Bucsics T; Simbrunner B; Scheiner B; Trauner M; Mandorfer M; Reiberger T; Bauer DJM
Gastroenterology; 2023 Oct; 165(4):1041-1052. PubMed ID: 37442301
[TBL] [Abstract][Full Text] [Related]
13. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
[TBL] [Abstract][Full Text] [Related]
15. CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
Wong YJ; Li J; Liu C; Chen Z; Chan YH; Putera M; Teh KB; Ang TL; Zhao L; Yan Z; Kumar R; Li X; Qi X
J Gastroenterol Hepatol; 2022 Jun; 37(6):1043-1051. PubMed ID: 35253271
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract][Full Text] [Related]
17. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
Wan T; Köhn N; Kröll D; Berzigotti A
Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
[TBL] [Abstract][Full Text] [Related]
18. Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
Wong YJ; Chen VL; Abdulhamid A; Tosetti G; Navadurong H; Kaewdech A; Cristiu J; Song M; Devan P; Tiong KLA; Neo JE; Prasoppokakorn T; Sripongpun P; Stedman CAM; Treeprasertsuk S; Primignani M; Ngu JH; Abraldes JG
Hepatology; 2024 Apr; ():. PubMed ID: 38630497
[TBL] [Abstract][Full Text] [Related]
19. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
[TBL] [Abstract][Full Text] [Related]
20. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
